Bahram Valamehr - Jul 6, 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief R&D Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Jul 6, 2022
Transactions value $
-$235,809
Form type
4
Date filed
7/7/2022, 04:04 PM
Previous filing
Mar 15, 2022
Next filing
Jul 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $9.68K +2K +1.11% $4.84 182K Jul 6, 2022 Direct F1
transaction FATE Common Stock Options Exercise $15.9K +5.84K +3.21% $2.73 188K Jul 6, 2022 Direct F1
transaction FATE Common Stock Sale -$236K -7.84K -4.18% $30.07* 180K Jul 6, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise -$9.68K -2K -18.68% $4.84 8.7K Jul 6, 2022 Common Stock 2K $4.84 Direct F1, F3
transaction FATE Stock Option (Right to Buy) Options Exercise -$15.9K -5.84K -16.16% $2.73 30.3K Jul 6, 2022 Common Stock 5.84K $2.73 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2020.
F2 Represents the weighted average sale price of the shares sold ranging from $30.00 to $30.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range set forth in footnote 2.
F3 This option is fully vested.